Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.…
COCP: Phase 1b Norovirus Challenge Study Results Near Year-End 2026
Cocrystal Pharma (NASDAQ: COCP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 10 employees.
The shares were at 0.9500 USD on 20 November 2026, down 13.6% over 52 weeks. Its 52-week range is 0.7600 USD to 2.030 USD: the price is 53.2% below the high and 25.0% above the low.
Its market capitalisation is 18.30M USD.
Cocrystal Pharma reports return on equity of -139.5%.
It holds more cash than debt, a net cash position of 3.62M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.